Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2778
Source ID: NCT00154401
Associated Drug: Liraglutide
Title: Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: liraglutide
Outcome Measures: Primary: HbA1c, after 14 weeks treatment | Secondary: Body weight after 14 weeks.|Glycaemic control parameters (fasting plasma glucose, glucose profiles) after 14 weeks.|Safety and tolerability
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 177
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2005-01
Completion Date: 2005-10
Results First Posted:
Last Update Posted: 2017-01-25
Locations: Novo Nordisk Investigational Site, Aalborg, 9000, Denmark|Novo Nordisk Investigational Site, Hellerup, 2900, Denmark|Novo Nordisk Investigational Site, Hvidovre, 2650, Denmark|Novo Nordisk Investigational Site, Kolding, 6000, Denmark|Novo Nordisk Investigational Site, København S, 2300, Denmark|Novo Nordisk Investigational Site, København, 2400, Denmark|Novo Nordisk Investigational Site, Køge, 4600, Denmark|Novo Nordisk Investigational Site, Århus C, 8000, Denmark|Novo Nordisk Investigational Site, Antibes, 06600, France|Novo Nordisk Investigational Site, DAX, 40107, France|Novo Nordisk Investigational Site, LA ROCHELLE cedex, 17019, France|Novo Nordisk Investigational Site, Marseille, 13009, France|Novo Nordisk Investigational Site, Montpellier, 34295, France|Novo Nordisk Investigational Site, Mougins, 06250, France|Novo Nordisk Investigational Site, Narbonne, 11108, France|Novo Nordisk Investigational Site, NEVERS cedex, 58033, France|Novo Nordisk Investigational Site, Nimes, 30006, France|Novo Nordisk Investigational Site, Pessac, 33600, France|Novo Nordisk Investigational Site, Rennes, 35056, France|Novo Nordisk Investigational Site, Venissieux, 69200, France|Novo Nordisk Investigational Site, Amsterdam, 1105 AZ, Netherlands|Novo Nordisk Investigational Site, Apeldoorn, 7334 DZ, Netherlands|Novo Nordisk Investigational Site, Den Bosch, 5223 GV, Netherlands|Novo Nordisk Investigational Site, Den Haag, 2512 VA, Netherlands|Novo Nordisk Investigational Site, Groningen, 9713 GZ, Netherlands|Novo Nordisk Investigational Site, Hengelo, 7555 DL, Netherlands|Novo Nordisk Investigational Site, Sliedrecht, 3361 XV, Netherlands|Novo Nordisk Investigational Site, Banska Bystrica, 95717, Slovakia|Novo Nordisk Investigational Site, Bratislava, 811 08, Slovakia|Novo Nordisk Investigational Site, Bratislava, 81526, Slovakia|Novo Nordisk Investigational Site, Bratislava, 82102, Slovakia|Novo Nordisk Investigational Site, Bratislava, 831 01, Slovakia|Novo Nordisk Investigational Site, Kosice, 040 01, Slovakia|Novo Nordisk Investigational Site, Kosice, 04011, Slovakia|Novo Nordisk Investigational Site, Kosice, 04190, Slovakia|Novo Nordisk Investigational Site, Lucenec, 98401, Slovakia|Novo Nordisk Investigational Site, Presov, 080 01, Slovakia|Novo Nordisk Investigational Site, Sahy, 93601, Slovakia|Novo Nordisk Investigational Site, Zilina, 01001, Slovakia
URL: https://clinicaltrials.gov/show/NCT00154401

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress